BRAF and colorectal carcinoma: Patients with CRC whose tumors harbor Class 2 and 3 BRAF mutations have been shown to have prolonged survival compared to those with Class 1 BRAF mutations, but are generally believed to be less responsive to MAPK-targeted therapies compared to Class 1 BRAF-mutant CRC [4,5].